Revance Therapeutics Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $521.18 million. The enterprise value is -$117.66 million.
Important Dates
The next confirmed earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 86.57 million shares outstanding. The number of shares has increased by 12.88% in one year.
| Current Share Class | 86.57M |
| Shares Outstanding | 86.57M |
| Shares Change (YoY) | +12.88% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 69.79% |
| Float | 64.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.71 |
| Forward PS | 2.71 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.43 |
| P/FCF Ratio | 4.71 |
| P/OCF Ratio | 4.69 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.07, with a Debt / Equity ratio of 0.05.
| Current Ratio | 8.07 |
| Quick Ratio | 7.93 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.18 |
| Interest Coverage | -126.91 |
Financial Efficiency
Return on equity (ROE) is -41.84% and return on invested capital (ROIC) is -28.07%.
| Return on Equity (ROE) | -41.84% |
| Return on Assets (ROA) | -19.60% |
| Return on Invested Capital (ROIC) | -28.07% |
| Return on Capital Employed (ROCE) | -31.11% |
| Revenue Per Employee | $354,120 |
| Profits Per Employee | -$947,328 |
| Employee Count | 192 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $2.24 million in taxes.
| Income Tax | 2.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.10% in the last 52 weeks. The beta is 0.41, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -71.10% |
| 50-Day Moving Average | 6.18 |
| 200-Day Moving Average | 8.73 |
| Relative Strength Index (RSI) | 44.86 |
| Average Volume (20 Days) | 1,296,938 |
Short Selling Information
The latest short interest is 8.41 million, so 9.71% of the outstanding shares have been sold short.
| Short Interest | 8.41M |
| Short Previous Month | 7.86M |
| Short % of Shares Out | 9.71% |
| Short % of Float | 13.11% |
| Short Ratio (days to cover) | 6.04 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $67.99 million and -$181.89 million in losses. Loss per share was -$2.09.
| Revenue | 67.99M |
| Gross Profit | -107.06M |
| Operating Income | -203.44M |
| Pretax Income | -181.75M |
| Net Income | -181.89M |
| EBITDA | -202.59M |
| EBIT | -203.44M |
| Loss Per Share | -$2.09 |
Full Income StatementBalance Sheet
The company has $658.19 million in cash and $19.35 million in debt, giving a net cash position of $638.84 million or $7.38 per share.
| Cash & Cash Equivalents | 658.19M |
| Total Debt | 19.35M |
| Net Cash | 638.84M |
| Net Cash Per Share | $7.38 |
| Equity (Book Value) | 364.41M |
| Book Value Per Share | 4.51 |
| Working Capital | 634.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $111.23 million and capital expenditures -$680,000, giving a free cash flow of $110.55 million.
| Operating Cash Flow | 111.23M |
| Capital Expenditures | -680,000 |
| Free Cash Flow | 110.55M |
| FCF Per Share | $1.28 |
Full Cash Flow StatementMargins
Gross margin is -157.46%, with operating and profit margins of -299.22% and -267.52%.
| Gross Margin | -157.46% |
| Operating Margin | -299.22% |
| Pretax Margin | -264.22% |
| Profit Margin | -267.52% |
| EBITDA Margin | -297.96% |
| EBIT Margin | -299.22% |
| FCF Margin | 162.60% |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.88% |
| Shareholder Yield | -12.88% |
| Earnings Yield | -34.90% |
| FCF Yield | 21.21% |
Analyst Forecast
The average price target for Kura Oncology is $24.50, which is 307.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.50 |
| Price Target Difference | 307.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 73.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of 0.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.35 |
| Piotroski F-Score | 3 |
